[Ip-health] picking one's competitors

[James Love]

Perhaps TAC can explain why the settlement will permit GSK and BI to
pick its competitors, and what are the consequences for this, and in
particular, how the settlement will affect CIPLA, a firm that was the
first the introduce 3 in 1 FDCs (for which is also has a patent for the
RSA market), that actually sought licenses from GSK and BI, a firm that
has been publicly challenging and embarassing big pharma on the patent
issue like no other generic firm, and a firm that placed ARV drugs in
the market in RSA following the CC's September announcement.

Will the TAC deal allow CIPLA to continue to sell ARV's in RSA, or will
it result in CIPLA having to remove its products, while GSK picks
generic competitors that it prefers?


   Jamie

--
James Love, Director, Consumer Project on Technology
http://www.cptech.org, mailto:james.love@cptech.org
tel. +1.202.387.8030, mobile +1.202.361.3040